Trump’s 100% Tariff on Branded Pharma Imports: Impact on India’s Generic Drug Industry & Stock Market
US President Donald Trump has announced a sweeping 100% import tariff on branded and patented pharmaceutical drugs, effective October 1, 2025. The move is aimed at pushing pharmaceutical companies to build manufacturing plants within the United States. While India’s generic drug exports appear safe for now, experts warn that any future extension of these tariffs to generics could disrupt India’s $30 billion pharma export market and shake investor confidence.
Continue Reading